Decision-theoretic designs for phase II clinical trials allowing for competing studies

Full text not archived in this repository.

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Stallard, N. (2003) Decision-theoretic designs for phase II clinical trials allowing for competing studies. Biometrics, 59 (2). pp. 402-409. ISSN 0006-341X doi: 10.1111/1541-0420.00047

Abstract/Summary

This article describes an approach to optimal design of phase II clinical trials using Bayesian decision theory. The method proposed extends that suggested by Stallard (1998, Biometrics54, 279–294) in which designs were obtained to maximize a gain function including the cost of drug development and the benefit from a successful therapy. Here, the approach is extended by the consideration of other potential therapies, the development of which is competing for the same limited resources. The resulting optimal designs are shown to have frequentist properties much more similar to those traditionally used in phase II trials.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/9455
Identification Number/DOI 10.1111/1541-0420.00047
Refereed Yes
Divisions Science > School of Mathematical, Physical and Computational Sciences > Department of Mathematics and Statistics > Applied Statistics
Uncontrolled Keywords Backward induction, Cost-benefit analysis, Optimal stopping, Sequential procedure
Download/View statistics View download statistics for this item

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar